You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
和鉑醫藥-B(02142.HK):B7H4X4-1BB雙特異性抗體(HBM7008) I期臨牀試驗完成首例患者首次給藥
格隆匯 05-25 16:36

格隆匯5月25日丨和鉑醫藥-B(02142.HK)發佈公吿,已完成B7H4x4-1BB雙特異性抗體HBM7008 的I期臨牀試驗首例患者給藥。該研究將評估HBM7008對實體瘤患者的安全性、耐受性、藥代動力學、藥效動力學及初步抗腫瘤活性。

HBM7008結合全人源轉基因小鼠和全人源僅重鏈抗體平台優勢,由其創新的免疫細胞銜接器HBICE®平台開發,是一款同時靶向腫瘤抗原B7H4和T細胞共刺激分子4-1BB的創新雙特異性抗體,其僅在與B7H4結合時,特異性激活T細胞,產生抗腫瘤活性。B7H4在多種惡性實體瘤中過度表達,包括乳腺癌、非小細胞肺癌、卵巢癌及子宮內膜癌。由於HBM7008對腫瘤具有交叉鏈接依賴性的表達特異性且具有高效的免疫調控活性,故在臨牀前研究中顯現卓越的安全性及強大的抗腫瘤療效,包括在小鼠腫瘤模型中觀察到完全緩解。

作為首款針對B7H4及4-1BB的雙特異性抗體,該產品有望引領下一代腫瘤免疫療法的發展。公司將繼續踐行全球創新發展戰略,全力推進該產品的全球臨牀開發專案。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account